With Medical Weight Loss, More Isn't Better: Why the Highest GLP-1 Dose Is Often the Wrong One
By Jill | Precision Health of Castle Rock
I see the same pattern almost every week. A patient comes to me after months on a GLP-1 medication prescribed somewhere else — a med spa, a telehealth subscription, a primary care office running twelve-minute visits. Their dose has climbed steadily since day one, not because their body asked for it, but because a calendar said it was time. Week four: increase. Week eight: increase. Week twelve: increase again. Nobody checked how they were tolerating it. Nobody looked at what they were losing — fat, or muscle, or both. They just kept turning the dial.
Some of these patients plateaued anyway. Others lost weight, but their face looks hollowed out, their neck skin has loosened, and they feel weaker walking up the same stairs that used to be effortless. They ask me the same question: "Isn't more supposed to mean better results?"
The honest answer is no. And the research backing that answer is more convincing than most patients — or, frankly, most prescribers — realize.
The Gap: Dosing by the Calendar, Not by the Patient
Here's where conventional GLP-1 prescribing has been getting it wrong. Most of the "start low, go slow" titration schedules patients are handed were built for one purpose: getting people up to the highest tolerable dose as quickly as the gastrointestinal system allows. The schedule is baked into the prescribing information, and once it starts, it runs on autopilot — a 2.5 mg increase every four weeks whether or not that particular patient is thriving on the dose they're already on.
This is the one-program-fits-all model. It treats every patient's biology as identical: same starting dose, same escalation interval, same ceiling. A recent real-world cohort study out of an academic obesity clinic found that titration patterns in everyday practice are frequently inconsistent with what actually drives results, and that provider inexperience with titration protocols is one of the likely reasons real-world weight loss so often falls short of what clinical trials reported. In other words, dosing decisions are being made on a timeline instead of a response curve.
A dose is not a finish line. It's a variable — and the right number is different for almost every person sitting in front of me.
What the Landmark Trials Actually Measured
This matters because so much of what patients (and providers) believe about GLP-1 efficacy comes from headlines built around the maximum dose studied in a trial, not the dose that's appropriate for an individual.
Look at the trial architecture itself. The SURPASS-2 trial, published in the New England Journal of Medicine, compared tirzepatide at 5 mg, 10 mg, and 15 mg against semaglutide at its highest approved dose of 1 mg — the ceiling, not a starting point. A 2025 network meta-analysis pooling more than 7,000 participants across eight randomized trials found a clear dose-response relationship: tirzepatide at its maximum tolerated dose produced roughly double the weight loss of the lowest dose studied. The SURMOUNT program followed the same logic, reporting headline results — 15% to 21% weight loss — from the highest dose arms.
None of this is wrong, exactly. It's how a pharmaceutical trial is designed to establish a ceiling of efficacy and safety. But it means the number that gets repeated in the news, on social media, and sometimes at the pharmacy counter is the number from patients pushed to their maximum tolerated dose — not the number for a person doing well, losing steadily, and staying metabolically and structurally intact at a lower one.
The Mechanism: Why More Milligrams Doesn't Mean More Fat Loss — It Means More Everything
GLP-1 receptor agonists work by slowing gastric emptying, increasing satiety signaling, and improving insulin secretion. Those effects don't scale up cleanly with dose in a way that only touches fat tissue. As the dose rises, appetite suppression intensifies — and so does the caloric deficit, often steeply. A body in a steep, sustained deficit doesn't selectively burn fat. It pulls energy from whatever is available, and skeletal muscle is very much on that list.
This is the part conventional dosing protocols routinely leave out of the conversation: multiple systematic reviews and network meta-analyses now show that lean mass accounts for roughly 25% to 30% of total weight lost on GLP-1 therapy, with some individual studies reporting ranges as wide as 15% to 60% depending on how aggressively the dose was escalated and how little structural support the patient had in place. The faster and higher the dose climbs without a counterbalance, the more of that weight loss comes from muscle rather than fat.
That distinction is not cosmetic. Muscle is metabolically active tissue. It's your insulin sensitivity, your resting metabolic rate, your fall-prevention system as you age, and one of the strongest predictors of long-term healthspan we have. Losing it as collateral damage from an oversized dose undermines the very metabolic goals the medication is supposed to serve.
Where This Shows Up: "GLP-1 Face," "GLP-1 Neck," and the Trends Nobody Warned You About
If you've spent any time on social media over the past year, you've seen the terms: "Ozempic face," "GLP-1 neck." Dermatology researchers now describe this pattern clinically — hollowed cheeks, sunken eyes, and loosened skin along the jaw and neck that make people look older, not just thinner. According to dermatologist Sabrina Fabi, MD, GLP-1 medications appear to interfere with the ability of fat-derived stem cells to regenerate collagen, elastin, and fat tissue in the skin, which compounds the effect of rapid volume loss with a reduced ability to bounce back from it.
The underlying driver is the same one we just walked through. When 25% to 40% of a patient's weight loss is lean tissue — muscle and the structural fat that supports skin — the face and neck are often where it shows up first and most visibly, because they have the least tissue reserve to begin with. This is not an inevitable side effect of the medication class. It's a predictable consequence of dosing too high, too fast, with no plan to protect the tissue that isn't supposed to be lost.
What We Do Differently at Precision Health
This is where the gap between conventional prescribing and the way I run my practice becomes very concrete.
1. We titrate to the patient, not the calendar.
Dose increases here are earned by data, not dictated by a date on a schedule. Before I move anyone up, I want to know: How is their appetite responding? What does GI tolerability look like? What is their body composition doing — not just the number on the scale, but the ratio of fat loss to lean mass loss? Plenty of patients do beautifully and lose weight steadily at doses well below the "maximum tolerated" ceiling that trial headlines are built around. For them, going higher isn't optimization. It's unnecessary risk.
2. We measure body composition, not just weight.
A scale can't tell you whether you're losing fat or losing yourself. We track body composition throughout treatment specifically so a plateau in total weight doesn't get mistaken for a lack of progress when fat is still dropping and muscle is being preserved — and so muscle loss gets caught and corrected before it becomes visible in the mirror.
3. We pair every prescription with a lifestyle protocol — because the research demands it.
A 2025 prospective study presented at a major endocrinology meeting followed 200 adults starting semaglutide or tirzepatide who received structured guidance on resistance training and protein intake from day one. At six months, they had lost roughly 13% of their body weight — but only about 3% of that was muscle, a dramatically smaller share than what's typically reported when medication is prescribed without that support. Separate consensus guidance from an international working group on GLP-1 therapy now recommends protein intake above 1.2 grams per kilogram of body weight daily, spread evenly across meals, combined with structured resistance training two to three times per week, specifically to protect lean mass during treatment.
That is the piece that gets skipped when a GLP-1 prescription is handed out without a broader plan: the medication does its job on appetite and insulin, but it was never designed to be the whole strategy. Eating enough protein, strength training consistently, staying hydrated, and getting adequate sleep aren't add-ons to a GLP-1 protocol — they're the difference between losing fat and simply losing weight.
The goal was never the smallest number on the scale. It's the healthiest version of you underneath it.
The Bigger Picture: Healthspan Over a Number on the Scale
At Precision Health, we don't measure success in pounds lost. We measure it in the quality of what's left standing at the end of treatment — muscle that still works, skin that still has the structure to support it, metabolic markers that have genuinely improved, and a body that's built to sustain the result rather than fight to regain it. Rapid, maximum-dose weight loss followed by muscle loss and skin laxity isn't a success story. It's a body pulled apart faster than it could adapt.
Longevity medicine is about protecting the systems that keep you capable and resilient decades from now, not just producing a dramatic before-and-after. A GLP-1 medication, dosed thoughtfully and paired with the right lifestyle scaffolding, is a genuinely powerful tool toward that goal. Dosed on autopilot, it can just as easily work against it.
The Bottom Line
More medication doesn't automatically mean more of the results you actually want. The trials that produced the headline weight-loss numbers were built around maximum tolerated doses — and real patients, dosed on a fixed calendar instead of their own response, are absorbing more muscle loss, more skin laxity, and more "GLP-1 face and neck" than they ever needed to. The right dose is the lowest one that gets you steady, sustainable progress — supported by enough protein, enough resistance training, and enough monitoring to know the difference between losing fat and losing yourself.
Ready for a Different Approach?
If you're on a GLP-1 medication and your dose has only ever gone up — never been evaluated, never been questioned — it might be time for a second opinion. At Precision Health of Castle Rock, we build individualized GLP-1 protocols around your body composition, your response, and a lifestyle plan designed to protect the muscle and metabolic health you're working so hard to gain. Schedule a consultation with Jill Hefti Breed, FNP-BC, and let's find the dose — and the plan — that's actually right for you.
Sources
Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." New England Journal of Medicine, 2021 (SURPASS-2).
Network meta-analysis of tirzepatide vs. semaglutide dose-response in weight loss, 7,179 participants across 8 RCTs. PMC, 2025.
Real-world titration, persistence, and effectiveness of GLP-1 receptor agonists in a multidisciplinary obesity clinic cohort. PMC, 2025.
Systematic review on muscle mass loss and GLP-1 receptor agonist therapy, including sarcopenia risk. PMC, 2025.
GLP-1 receptor agonists and sarcopenia: a narrative review of 22 RCTs and 2,258 participants. ScienceDirect, 2025.
SEMALEAN study: Impact of semaglutide on fat mass, lean mass, and muscle function in patients with obesity. PMC, 2025.
Systematic review and network meta-analysis of body composition changes with GLP-1 receptor agonists and co-agonists. ScienceDirect, 2024.
Fabi S, MD, as cited in "The science behind 'Ozempic face': How to improve GLP-1-related skin sagging." Healio, August 2025.
GLP-1 receptor agonists and possible mechanisms of skin aging. PMC, 2025.
Peralta-Reyes D, et al. Resistance training and protein intake study on lean mass preservation during GLP-1 RA therapy, presented 2025; reported via Medscape, April 2025.
LEAN-PREP study protocol: Lean mass preservation with resistance exercise and protein during semaglutide and tirzepatide therapy (registered randomized controlled trial). PubMed, 2025.
Consensus recommendations on optimizing GLP-1 therapies with nutrition and lifestyle interventions, 42nd International Symposium on Diabetes and Nutrition. ScienceDirect, 2025.
